TY - JOUR
T1 - Use of microarrays in the clinical practice of pediatric rheumatology
T2 - The future is now?
AU - Punaro, Marilynn
PY - 2014/9
Y1 - 2014/9
N2 - PURPOSE OF REVIEW: Systems immunology is an integrative approach that leverages high throughput technologies as well as mathematical and computational tools to investigate complex immunologic diseases by looking at the state of a system on a comprehensive scale. Gene expression profiling, also known as transcriptomics, measures the expression level of mRNAs (transcripts) in a given cell population at a specific time. Over the past decade, several major gene expression discoveries have been made in pediatric rheumatology, most notably the alpha interferon signature of systemic lupus erythematosus and the interleukin-1 signature in systemic onset juvenile idiopathic arthritis. This article reviews these discoveries, their clinical implications and the recent associated literature. RECENT FINDINGS: Interferon-α has been exploited as a therapeutic target in lupus. Interleukin-1 blockade has been utilized to treat systemic onset juvenile idiopathic arthritis and related autoinflammatory diseases. SUMMARY: Current gene expression studies extend our understanding of the disease pathogenesis of lupus and systemic onset juvenile idiopathic arthritis as well as related conditions. This knowledge has translated to the bedside with implications for clinical practice and direct therapeutic targeting.
AB - PURPOSE OF REVIEW: Systems immunology is an integrative approach that leverages high throughput technologies as well as mathematical and computational tools to investigate complex immunologic diseases by looking at the state of a system on a comprehensive scale. Gene expression profiling, also known as transcriptomics, measures the expression level of mRNAs (transcripts) in a given cell population at a specific time. Over the past decade, several major gene expression discoveries have been made in pediatric rheumatology, most notably the alpha interferon signature of systemic lupus erythematosus and the interleukin-1 signature in systemic onset juvenile idiopathic arthritis. This article reviews these discoveries, their clinical implications and the recent associated literature. RECENT FINDINGS: Interferon-α has been exploited as a therapeutic target in lupus. Interleukin-1 blockade has been utilized to treat systemic onset juvenile idiopathic arthritis and related autoinflammatory diseases. SUMMARY: Current gene expression studies extend our understanding of the disease pathogenesis of lupus and systemic onset juvenile idiopathic arthritis as well as related conditions. This knowledge has translated to the bedside with implications for clinical practice and direct therapeutic targeting.
KW - autoinflammatory diseases
KW - gene expression profiling
KW - pediatric lupus
KW - systemic onset juvenile idiopathic arthritis
UR - http://www.scopus.com/inward/record.url?scp=84905440601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905440601&partnerID=8YFLogxK
U2 - 10.1097/BOR.0000000000000095
DO - 10.1097/BOR.0000000000000095
M3 - Review article
C2 - 25014037
AN - SCOPUS:84905440601
SN - 1040-8711
VL - 26
SP - 585
EP - 591
JO - Current Opinion in Rheumatology
JF - Current Opinion in Rheumatology
IS - 5
ER -